SCHEMBL2107350

SCHEMBL2107350

Fc1cc2[nH]c(=S)[nH]c2cc1F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.70
TDP1 Q9NUW8 2/20 0.70
PDE7A Q13946 1/20 0.67
PDE7B Q9NP56 1/20 0.67
HPGD P15428 5/20 0.55
KDM4E B2RXH2 4/20 0.55
MAPT P10636 4/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HSD17B10 Q99714 4/20 0.46
PSMB8 P28062 2/20 0.46
POLB P06746 2/20 0.46
ALOX15 P16050 2/20 0.46
TSHR P16473 2/20 0.46
APOBEC3G Q9HC16 2/20 0.46
HAVCR2 Q8TDQ0 1/20 0.46
CYP3A4 P08684 1/20 0.46
GFER P55789 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19886183 0.85 ALDH1A1 (0.59) ALDH1A1TDP1PDE7APDE7BHPGD
SCHEMBL17432052 0.83 ALDH1A1 (1.00) ALDH1A1TDP1PDE7APDE7BHPGD
SCHEMBL2106255 0.76 ALDH1A1 (0.50) ALDH1A1TDP1PDE7APDE7BHPGD
SCHEMBL4030881 0.74 KDM4E (0.61) ALDH1A1TDP1PDE7APDE7BHPGD
SCHEMBL7631915 0.71 ALDH1A1 (0.70) ALDH1A1TDP1PDE7APDE7BHPGD
SCHEMBL123451 0.71 KDM4E (0.58) ALDH1A1HPGDKDM4EMAPTMEN1
SCHEMBL3786399 0.71 PDE3B (0.50) ALDH1A1TDP1PDE7APDE7BKDM4E
SCHEMBL7116569 0.67 KDM4E (1.00) ALDH1A1TDP1HPGDKDM4EMAPT
SCHEMBL2104541 0.66 ALDH1A1 (0.43) ALDH1A1TDP1PDE7APDE7BHPGD
SCHEMBL16208357 0.64 ALDH1A1 (0.56) ALDH1A1TDP1HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163768-B2 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus AVENTIS PHARMA S.A.. (FR) 2012-04-24 US disclosed
EP-1910366-B1 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM AVENTIS PHARMA SA (FR) 2011-08-24 EP disclosed
US-20080261969-A1 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them AVENTIS PHARMA S.A. (FR) 2008-10-23 US disclosed
EP-1910366-A2 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM Aventis Pharma S.A. (FR) 2008-04-16 EP disclosed
WO-2007012972-A2 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261969-A1 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them DPYD, DHPS, QDPR ALDH1A1 191/4885TDP1 1344/4885PDE7A 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.